Inspired by patients and families around the world
Soleno Therapeutics is a publicly traded biopharmaceutical company (NASDAQ: SLNO) focused on developing and commercializing novel therapeutics for rare genetic disorders. Their first commercial product, VYKAT XR (diazoxide choline extended-release tablets), received FDA approval in March 2025 as a once-daily oral treatment for hyperphagia in patients with Prader-Willi syndrome aged 4 and older. The company is headquartered in Redwood City, California.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNo funding data available yet.
Know something? Help us improve our data.
Create a free account to see which investors have funded this company.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
